Product
TKI+Cardunilimab
1 clinical trial
1 indication
Indication
Hepatocellular CarcinomaClinical trial
Evaluation of the Efficacy and Safety of Cardonilimab Injection Combined With TKI as Second-line Treatment for Advanced Hepatocellular Carcinoma: A Single-arm, Open-label, Multicenter Real-world Clinical StudyStatus: Recruiting, Estimated PCD: 2026-01-01